- Home
- LIEN vs CRGX Comparison
LIEN vs CRGX Comparison
Compare LIEN & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- CRGX
- Stock Information
- Founded
- LIEN 2021
- CRGX 2021
- Country
- LIEN United States
- CRGX United States
- Employees
- LIEN N/A
- CRGX N/A
- Industry
- LIEN
- CRGX
- Sector
- LIEN
- CRGX
- Exchange
- LIEN NYSE
- CRGX Nasdaq
- Market Cap
- LIEN 234.6M
- CRGX 213.5M
- IPO Year
- LIEN 2022
- CRGX 2023
- Fundamental
- Price
- LIEN $9.88
- CRGX $3.97
- Analyst Decision
- LIEN Hold
- CRGX Hold
- Analyst Count
- LIEN 1
- CRGX 7
- Target Price
- LIEN N/A
- CRGX $4.67
- AVG Volume (30 Days)
- LIEN 20.2K
- CRGX 723.6K
- Earning Date
- LIEN 05-14-2025
- CRGX 05-23-2025
- Dividend Yield
- LIEN 13.59%
- CRGX N/A
- EPS Growth
- LIEN N/A
- CRGX N/A
- EPS
- LIEN 0.93
- CRGX N/A
- Revenue
- LIEN $21,665,753.00
- CRGX N/A
- Revenue This Year
- LIEN $102.44
- CRGX $58.18
- Revenue Next Year
- LIEN N/A
- CRGX N/A
- P/E Ratio
- LIEN $10.75
- CRGX N/A
- Revenue Growth
- LIEN 81.56
- CRGX N/A
- 52 Week Low
- LIEN $9.71
- CRGX $3.00
- 52 Week High
- LIEN $13.38
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- CRGX 36.42
- Support Level
- LIEN N/A
- CRGX $3.97
- Resistance Level
- LIEN N/A
- CRGX $4.32
- Average True Range (ATR)
- LIEN 0.00
- CRGX 0.20
- MACD
- LIEN 0.00
- CRGX -0.05
- Stochastic Oscillator
- LIEN 0.00
- CRGX 0.00
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.